youtube_live
Fitimet për Q2 2026 • pas 2 ditësh
Shiko detajetchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,91 US$
arrow_downward
-4,34%(-1,13) 1D
25,00 US$
arrow_upward
+0,36% (+0,090)bedtimeJashtë orarit
Mbyllur: 31 korr, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
1D
5D
1M
6M
YTD
1V
5V
Maks
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për RARE...
Hap
25,95 US$
I lartë
26,08 US$
I ulët
24,60 US$
Kapitalizimi i tregut
2,45 mld
Vëllimi mesatar
2,76 mln
Vëllimi
1,54 mln
Maksimumi 52-javor
39,89 US$
Minimumi 52-javor
18,29 US$
Fitimet për aksion
-6,10 US$
Beta
0,31
Aksionet në qarkullim
98,49 mln
Numri i punonjësve
1 mijë
Hap
25,95 US$
I lartë
26,08 US$
I ulët
24,60 US$
Kapitalizimi i tregut
2,45 mld
Vëllimi mesatar
2,76 mln
Vëllimi
1,54 mln
Maksimumi 52-javor
39,89 US$
Minimumi 52-javor
18,29 US$
Fitimet për aksion
-6,10 US$
Beta
0,31
Aksionet në qarkullim
98,49 mln
Numri i punonjësve
1 mijë
Lajmet
Nga burimet nëpër ueb
https://www.dars.gov.et/
·
1 muaj më parë
Ultragenyx Q1 2026 Earnings: EPS Misses Estimates, Stock Gains on Strategic Optimism - Debt Analysis Report
Profili
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Rreth Ultragenyx Pharmaceutical Inc
Drejtori ekzekutivEmil Kakkis
Punonjësit1,37 mijë
Themeluar më2010
SeliaNovato, Kalifornia, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtiultragenyx.com
Përmbajtjet me IA mund të përfshijnë gabime. Mëso më shumë